Companies in #Rare Disease Therapeutics
Found 1 company operating in this sector.
Eton Pharmaceuticals is a commercial-stage specialty pharmaceutical company developing, acquiring, and commercializing high-potential therapies for the treatment of rare diseases. The company's commercial portfolio includes Alkindi Sprinkle (hydrocortisone pediatric granules), Carglumic Acid (N-carbamylglutamate for hyperammonemia), Rezipres (ephedrine injection), and Betaine Anhydrous. Eton also operates a royalty-monetization business that has provided non-dilutive capital to fund late-stage clinical assets in-licensed from larger developers. In July 2026, Canaccord Genuity raised its price target on Eton to $60, citing accelerating rare-disease commercial momentum.